论文部分内容阅读
目的观察大剂量应用复方苦参注射液联合多西他赛治疗中晚期非小细胞肺癌的安全性和有效性。方法选取明确病理诊断为中晚期非小细胞肺癌的患者117例,根据不同治疗方法分为观察组59例和对照组58例,观察组应用大剂量复方苦参注射液(20 ml/d)联合多西他赛化疗;对照组单用多西他赛化疗。结果观察组患者的疾病控制率为88.1%,明显高于对照组的48.3%,差异有统计学意义(P<0.05);观察组与对照组治疗前后白细胞及中性粒细胞比较,观察组明显低于对照组,差异有统计学意义(P<0.05)。结论复方苦参注射液联合多西他赛可改善患者生存质量,改善化疗对肺癌患者的免疫抑制状态,对治疗中晚期非小细胞肺癌是安全、有效的。
Objective To observe the safety and efficacy of high-dose compound Kushen injection combined with docetaxel in the treatment of advanced non-small cell lung cancer. Methods A total of 117 patients with pathologically confirmed advanced non-small cell lung cancer (NSCLC) were enrolled in this study. They were divided into observation group (n = 59) and control group (n = 58) according to different treatment methods. The observation group was treated with high dose Compound Kushen Injection (20 ml / d) Docetaxel chemotherapy; control group docetaxel chemotherapy alone. Results The disease control rate in the observation group was 88.1%, which was significantly higher than that in the control group (48.3%), the difference was statistically significant (P <0.05). Compared with the control group before and after treatment, the observation group was significantly Lower than the control group, the difference was statistically significant (P <0.05). Conclusion Compound Kushen injection combined with docetaxel can improve the quality of life of patients and improve the immunosuppressive status of patients with lung cancer by chemotherapy. It is safe and effective in the treatment of advanced non-small cell lung cancer.